Compounds > pyrazinoic acid

pyrazinoic acid and 5-chloropyrazinamide

pyrazinoic acid has been researched along with 5-chloropyrazinamide in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (57.14)	29.6817
2010's	3 (42.86)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arai, M; Jacobs, WR; Vilchèze, C; Welch, JT; Zimhony, O	1
Chung, WJ; Jacobs, WR; Ngo, SC; Sayahi, H; Welch, JT; Zimhony, O	1
Baughn, AD; Deng, J; Jacobs, WR; Riestra, A; Vilchèze, C; Welch, JT; Zimhony, O	1
Bolívar, BE; Welch, JT	1
Cox, JS; Jacobs, WR; Vilchèze, C; Welch, JT; Zimhony, O	1
Barry, CE; Boshoff, HI; Mizrahi, V	1
Baughn, AD; Dillon, NA; Peterson, ND; Rosen, BC	1

Other Studies

7 other study(ies) available for pyrazinoic acid and 5-chloropyrazinamide

Article	Year
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2 Topics: Bacterial Proteins; Fatty Acid Synthases; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide; Structure-Activity Relationship; Tuberculosis	2007
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Bacterial Proteins; Cell-Free System; Fatty Acid Synthases; Humans; Inhibitory Concentration 50; Kinetics; Mass Spectrometry; Molecular Structure; Mycobacterium tuberculosis; NADP; Oxidation-Reduction; Pyrazinamide; Reproducibility of Results; Substrate Specificity	2007
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:12 Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Genotype; Mutation; Mycobacterium bovis; Mycobacterium smegmatis; Mycobacterium tuberculosis; Pyrazinamide	2010
Studies of the Binding of Modest Modulators of the Human Enzyme, Sirtuin 6, by STD NMR. Chembiochem : a European journal of chemical biology, 2017, 05-18, Volume: 18, Issue:10 Topics: Binding Sites; Crystallography, X-Ray; Humans; Kinetics; Magnetic Resonance Imaging; Niacinamide; Protein Binding; Pyrazinamide; Sirtuins; Thermodynamics	2017
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nature medicine, 2000, Volume: 6, Issue:9 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Enzyme Inhibitors; Fatty Acid Synthases; Humans; Mycobacterium tuberculosis; Prodrugs; Pyrazinamide; Tuberculosis, Pulmonary	2000
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. Journal of bacteriology, 2002, Volume: 184, Issue:8 Topics: Antitubercular Agents; Bacterial Proteins; Fatty Acid Synthases; Fatty Acids; Hydrogen-Ion Concentration; Mycobacterium tuberculosis; Pyrazinamide	2002
Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:12 Topics: Antitubercular Agents; beta-Alanine; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Niacinamide; Pantetheine; Pantothenic Acid; Pyrazinamide	2014